AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01950689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimorazole
Study NCT01950689 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT01950689 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Study NCT03810300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash transfer
Description: 1500 taka ($18.75) per household distributed monthly
Study NCT01860755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control postural education, general range of motion and strengthening in addition to the standard of care
Description: Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
Study NCT01860755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control postural education, general range of motion and strengthening in addition to the standard of care
Description: Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
Study NCT01860755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport.
Study NCT01077947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional anesthetic discography
Description: Functional anesthetic discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
Study NCT01077947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Provocative Discography
Description: Provocative Discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
Study NCT04098107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Throwing Device
Description: The Innovative Design Labs ( IDL) PhySens will be used to monitor the physical motions of subjects during standard sports-related actions (e.g. throwing a baseball). For this test, the PhySens Carrier will be attached via clothing rivets to a fabric sleeve or strap made of compliant materials commonly used in clothing and wearable products (e.g. nylon, spandex, neoprene).
Study NCT01792947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous electroneurostimulation of dermatome T6
Description: The patients underwent a percutaneous electroneurostimulation of dermatome T6 during 30 minutes, every week during 12 weeks. This intervention was associated to a diet 1200 Kcal
Study NCT03810300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food transfer
Description: 30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
Study NCT01792947 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet 1200 Kcal
Description: The patients assigned to this group must follow a 1200 Kcal diet during months
Study NCT01792947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet 1200 Kcal
Description: The patients assigned to this group must follow a 1200 Kcal diet during months
Study NCT02140788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT02140788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Study NCT02538705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neovasculgen
Study NCT04692428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Locoregional analgesia
Description: the supra-inguinal fascia iliaca block versus the femoral nerve block
Study NCT02311738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training intensity intervention
Description: High intensity training group describes the group performing high intensity exercise intervention. Moderate intensity training group describes the the group performing moderate exercise intervention
Study NCT02369341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix Tetra
Description: One dose of the Fluarix™ Tetra vaccine was administered to all subjects on Day 0 (Visit 1) intramuscularly into the deltoid of the non-dominant arm.
Study NCT03930888 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary supplement
Description: Patients with preoperative nutritional support with special nutritional supplements vs. patients without special nutritional support.
Study NCT00706979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Quit Attempt plus nicotine lozenge
Description: nicotine lozenge, 2 mg or 4 mg
Study NCT00706979 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Practice Quit Attempt only
Description: Practice Quit Attempts (PQA) message aided by brief advice and self-help materials
Study NCT00930579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1500 mg per day, divided 500 mg in the morning and 1000 mg in the evening, for at least two weeks prior to surgery
Study NCT03811431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast enhanced ultrasound guided liver biopsy
Description: Conventional liver biopsy
Study NCT00729027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg/day AVE5530
Description: * one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)
Study NCT00729027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg/day AVE5530
Description: * one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)
Study NCT00729027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: * one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)
Study NCT04323280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy
Description: Dexamethasone 20MG once daily for 4 days with additional colchicine therapy for 3 months
Study NCT04323280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID therapy
Description: NSAIDS (Ibuprofen or Aspirin) or Glucocorticoid (Prednisone) therapy for 3 weeks with addional colchicine therapy for 3 months
Study NCT03411681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Participants will perform 4 sets of 12 repetitions of moderate intensity leg extension
Study NCT03411681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants will perform 4 sets of 12 repetitions of moderate intensity leg extension
Study NCT04536155 — intervention group
Intervention type: OTHER
Intervention: questionnary SF36
Description: This is a validate questionnary:~Ware et al,1992, McHorney et al, 1993, McHorney et al, 1994 French version : Author : Alain Leplège; et coll. En 2001
Study NCT04536155 — intervention group
Intervention type: OTHER
Intervention: Hospital Anxiety and Depression Scale
Description: this is a validate scale: author: Zigmond A.S., Snaith R.P. in 1983
Study NCT04536155 — intervention group
Intervention type: OTHER
Intervention: Chronic Pain Acceptance Questionnaire
Description: This is a validate questionnaire:~Fish, R., McGuire, B.E., Hogan, M., Stewart, I. \& Morrison, T. (2010).
Study NCT04536155 — intervention group
Intervention type: OTHER
Intervention: digital pain scale
Description: this is a validate scale A.N.A.E.S. February 1999
Study NCT01312818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m\^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1, 4, 8 and 11.
Study NCT01312818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 180 mg/m\^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14
Study NCT01312818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 6 mg/m\^2 by mouth (PO) divided twice a day (BID) on days 4-15.
Study NCT01312818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)
Study NCT01312818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: For Ph+ acute lymphoblastic leukemia (ALL) patients only:~Imatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for >18 years on Days 1-16.
Study NCT01232920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: All methotrexate doses will be taken orally once per week in a divided dose (half in the morning, half in the evening), and should be taken with food. For the first two weeks, a loading dose of 15 mg/week orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 25 mg/week until the end of follow-up or until treatment failure due to intolerability, adverse events, or of lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 20 mg per week while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 15 mg per week.
Study NCT01232920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil will be taken twice daily on an empty stomach. For the first two weeks, a loading dose of 500 mg/BID orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 1 g/BID until the end of follow-up or until treatment failure due to intolerability, adverse events, or lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 750 mg/BID while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 500 mg/BID.
Study NCT01514760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile-based Asthma Action Plan
Description: The participant will be distributed a mobile phone (iPhone or Android) at the time of consent. The mobile-based Asthma Action Plan application will be provided on the mobile device. The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts. Participants will receive 3 daily messages from the Asthma Action Plan mobile application. A fourth rotating message will be sent twice weekly.
Study NCT00299260 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CMV gB vaccine
Description: 20 micrograms
Study NCT00299260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline
Study NCT03975855 — intervention group
Intervention type: DEVICE
Intervention: NeoNavia® Biopsy System
Description: Biopsy of axillary lymph node using the NeoNavia Biopsy System. The investigator shall obtain as many/large samples as judged adequate and sufficient for diagnosis.
Study NCT04349618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PROTECTIVE VENTILATION
Description: Protective ventilation with tidal volume 6 mL/kg of predicted body weight further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20, and PEEP set using the PEEP FiO2 table of the ARMA trial
Study NCT04349618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ULTRAPROTECTIVE VENTILATION
Description: Ultraprotective ventilation with tidal volume reduction down to 4 mL/kg further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20, and PEEP set using the PEEP FiO2 table of the ARMA trial
Study NCT04577287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Cathodal/Anodal tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
Study NCT01902342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg 1 cap
Study NCT01224847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracaine
Description: 1 gtt
Study NCT03810300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food and cash transfer
Description: 15 kg of rice, 1 kg of lentils, and 1 kg of micronutrient-fortified cooking oil, and 750 taka cash per household, distributed monthly
Study NCT03810300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition behavior Communication Change (BCC)
Description: Weekly, group-based, one-hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings
Study NCT03810300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No transfer, no behavior change communication
Study NCT04372732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum tumor autoantibody detection
Description: All enrolled patients will be tested for ten kinds of tumor autoantibodies using peripheral blood before PD-1 bloackade treatment.
Study NCT04528602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control (Extended leg position) Group
Description: Common procedure steps -Legal representatives of the infants will sign an informed consent form. Materials (soap, napkin, non-sterile gloves, diaper, wet cotton towels for newborns, waste container, diaper change mat) will be prepared.~Hands will be washed and gloves will be worn. Tapes of the infant's dirty diaper will be opened.~For the Control Group~-The infant will be grasped on the legs, the legs will be given extension position and lifted up.~The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~The infant's feet will be freed. The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed.~The infant's legs will be given in extension position and a clean diaper will be placed under them.~Tapes of the clean diaper will be fastened. Hands will be washed after the procedure Data will be collected before, during, after and 3 minutes after application.
Study NCT04528602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental (Legs are flexed toward abdomen) Group
Description: Procedure steps for the Experimental Group~* Common procedure steps~* The infant will be grasped on the legs; the legs will be kept in the flexion position and approached toward the abdomen.~* The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~* The infant's feet will be freed.~* The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed and thrown into the medical waste bin.~* The infant's legs will be kept in the flexion position and a clean diaper will be placed under them. A bottom care plan will be applied in line with the treatment plan, if necessary.~* Tapes of the clean diaper will be fastened.~* Hands will be washed after the procedure.~* Data will be collected immediately before, during, immediately after and 3 minutes after the end of application.
Study NCT01285167 — intervention group
Intervention type: DRUG
Intervention: Daxas
Description: 500 microgram, oral, once daily as add-on therapy to existing therapy
Study NCT03733860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cavernous tissue sparing penile prosthesis implantation
Description: Beginning penile prosthesis implantation (Coloplast Titan USA) procedure after intracavenosal injection of PGE1 prostine.
Study NCT03733860 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional penile prosthesis implantation
Description: Beginning penile implant procedure (Coloplast Titan USA) without prior intracavernosal injection of PGE1 prostine
Study NCT03733860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracavernosal injection of alprostadil
Description: Intraoperative intracavernosal injection of alprostadil in the cavernous sparing group
Study NCT03374423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency
Description: The procedure will be done under propofol sedation, under fluoroscopic guidance. The image intensifier will be rotated in a cephalo-caudal direction until the endplates of the thoracic vertebrae are aligned and the transverse processes became discernable from the ribs.~For the intercostal nerve group, the radiofrequency needle 10 cm with 10 ml active tip will then inserted to contact the lower edge of the transverse process of (T2-T5), the needle is walked off to obtain sensory stimulation between 0.3-0.6 mv and motor stimulation less than 1.2 mv .five cycle of pulsed radiofrequency will be delivered.
Study NCT03374423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency
Description: The procedure will be done under propofol sedation, under fluoroscopic guidance.for dorsal root ganglion group, radiofrequency needle 10 cm with 10 ml active tip will inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walked into the thoracic intervertebral foramen. Once correct needle position is confirmed, test stimulation will be performed at 50 Hz, during which time the needles will slightly redirected to optimize stimulation, the point of maximum stimulation will be designated to be the location of the dorsal root ganglion. five cycle of pulsed radiofrequency will be delivered.
Study NCT02249858 — intervention group
Intervention type: PROCEDURE
Intervention: Cranial Vault Hold
Study NCT02343718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Study NCT02248402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vax-DC/MM
Study NCT02937766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Study NCT02937766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Study NCT01224847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocaine
Description: 1 gtt
Study NCT01224847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine soaked pledget
Study NCT02249858 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical HVLA
Study NCT03171142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heliox
Description: Heliox (21:79) via nasal cannula 2 litter per minutes
Study NCT03171142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Air
Description: Air 21% via nasal cannula 2 litter per minutes
Study NCT02127242 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ureteroscopic air-pressure ballistic lithotripsy
Description: In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
Study NCT00596622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
Study NCT03181139 — intervention group
Intervention type: OTHER
Intervention: ERAS pathway for Total Mastectomy
Description: Enhanced Recovery after Surgery (ERAS) pathway for Total Mastectomy
Study NCT03422536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT03422536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab
Description: Given IV
Study NCT01694108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG-vaccine (SSI)
Study NCT03976999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: * Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)~* Tissue samples (tumor tissue and healthy tissue) collected during the surgery
Study NCT03149029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a type of antibody that inhibits the cancer cell growth
Study NCT03149029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib is also a cell inhibitor and works by stopping the cancer cell from duplicating
Study NCT03149029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is a cell inhibitor that binds to the cancer cells to inhibit the cancer cells' signals to decrease cell growth
Study NCT04093986 — intervention group
Intervention type: OTHER
Intervention: Chart Review
Description: Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.